Analysts predict that Omega Therapeutics Inc (NASDAQ:OMGA) will announce earnings per share (EPS) of ($0.57) for the current quarter, according to Zacks. Zero analysts have made estimates for Omega Therapeutics’ earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.46). The company is scheduled to report its next quarterly earnings results on Wednesday, February 9th.
According to Zacks, analysts expect that Omega Therapeutics will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($3.87) to ($1.77). For the next fiscal year, analysts expect that the company will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.73) to ($2.56). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Omega Therapeutics.
Omega Therapeutics (NASDAQ:OMGA) last released its earnings results on Wednesday, November 10th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.09).
Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in shares of Omega Therapeutics during the third quarter worth $4,168,000. BlackRock Inc. bought a new stake in Omega Therapeutics in the 3rd quarter valued at $18,061,000. CHI Advisors LLC acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $19,904,000. 72 Investment Holdings LLC acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $6,653,000. Finally, Sphera Funds Management LTD. acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $9,952,000. 54.25% of the stock is currently owned by institutional investors.
Shares of NASDAQ OMGA traded down $0.32 during mid-day trading on Thursday, hitting $17.00. The company had a trading volume of 97,474 shares, compared to its average volume of 101,414. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.62 and a current ratio of 16.69. The firm’s 50-day moving average price is $21.19. Omega Therapeutics has a 12 month low of $15.50 and a 12 month high of $31.41.
Omega Therapeutics Company Profile
Omega Therapeutics Inc is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc is based in CAMBRIDGE, Mass.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.